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Background: The clinical usefulness of flow cytometry (FCM) for the diagnosis of lepto-
meningeal diseases (LMD) in non-Hodgkin lymphomas has been suggested in previous 
studies but needs to be further validated. With this regards, we evaluated the use of FCM 
for LMD in a series of Korean patients with non-Hodgkin lymphoma. 
Methods: FCM and cytomorphology were conducted using samples obtained from clini-
cally suspected LMD patients, follow-up LMD patients, and those with high risk of devel-
oping tumorigenic diseases. We then compared results of FCM and cytomorphology. In 
total, 55 and 47 CSF samples were analyzed by FCM and cytomorphology, respectively.
Results: Of the samples analyzed, 25.5% (14/55) and 12.8% (6/47) were positive by 
FCM and cytomorphology, respectively. No samples were determined as negative by FCM 
but positive by cytomorphology. Seven patients were positive only by FCM and negative by 
cytomorphology, and six among them were clinically confirmed to have LMD either by fol-
low-up cytomorphology or imaging study.
Conclusions: We observed a high detection rate of tumor cells by FCM compared with cy-
tomorphology. FCM study can be useful in early sensitive detection of LMD.
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INTRODUCTION
Leptomeningeal disease (LMD) is a fatal complication of non-
Hodgkin lymphoma (NHL); therefore, early and accurate diagno-
sis of LMD is important for the management of NHL. Although 
conventional cytomorphology is considered as the standard 
method for the diagnosis of LMD, its utility is limited owing to a 
low sensitivity with a false-negative rate of 20-60% [1, 2]. Flow 
cytometry (FCM) has been used for rapid and sensitive diagnosis 
of various hematologic malignancies [3, 4]. FCM analysis has also 
been demonstrated as an excellent diagnostic tool for detecting 
leukemia and lymphoma cells in various body fluids [5, 6]. 
The utility of FCM for detecting LMD in cerebrospinal fluid 
(CSF) has also been evaluated in some previous studies, show-
ing promising results [3, 7]. However, the techniques are tricky 
owing to the low cell counts, high proportion of non-viable cells 
in CSF, and necessity for implementing multi-color FMC antibod-
ies. Furthermore, clinical testing methods have not been stan-
dardized yet. Because the testing was validated only in a limited 
number of clinical cohorts, the method and its clinical implica-
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tions should be further validated in various clinical settings.
In the present study, we explored the clinical usefulness of 
FCM for the diagnosis of LMD in a series of Korean NHL patients 
in comparison with the traditional cytology method. In addition, 
we analyzed the prognostic effect of LMD confirmed by FCM.
METHODS
1. Patient enrollment
CSF specimens were obtained in patients with clinically sus-
pected LMD (headache, mental change, paralysis and/or other 
neurologic sign and symptoms) or high risk diseases (Burkitt 
lymphoma or multiple metastases of primary tumors) from 
March 2013 to May 2014 at Samsung Medical Center in Seoul, 
Korea. For each specimen, cytomorpholgical and FCM analyses 
were conducted. A total of 55 samples from 30 patients, includ-
ing 26 males and 4 females (mean age: 51 yr) were analyzed 
by using FCM, and 47 of them were also analyzed by cytomor-
phology in parallel. Eight samples were collected at initial work-
up, and the others were obtained during follow-up periods. Dif-
fuse large B cell lymphoma (DLBCL) was the most common 
neoplasm analyzed, and cases of other rare lymphomas includ-
ing extranodal NK/T cell lymphoma (ENKTL), anaplastic large 
cell lymphoma (ALCL) and Burkitt lymphoma (BL) were also in-
cluded (Supplemental Data Table 1). The number of CD45-pos-
itive cells acquired by the FCM instrument ranged from 387 to 
1,568,515.
The medical records were reviewed in detail for all cases of 
FCM and cytomorphology to analyze overall survival (OS). The 
current study was based on an analysis of routine clinical test 
results with patients’ consent, and the approval of institutional 
review board was waived.
2. Flow cytometric analysis of lymphoma cells
FCM analysis was done on the FACSCantoII flow cytometer 
(Becton Dickinson, San Jose, CA, USA) and the Kaluza software 
(Beckman Coulter, Brea, CA, USA). Compensation matrix was 
calculated by using BD CompBead particles (Becton Dickinson) 
and the compensation setup tool in BD FACSDiva software. The 
minimum white blood cell (WBC) count in CSF was 1×106/L (1-
1,530×106/L).
For mature B-cell malignancy, 7-aminoactinomycin D (7-AAD) 
and a combination of antibodies including CD45-allophycocya-
nin-cyanine7 (APC-Cy7), CD19-APC, surface kappa-fluorescein 
isothiocyanate (FITC), and surface lambda-phycoerythrin (PE) 
were used. The criteria for determining the results were accord-
ing to previous literatures [7-9] and as follows: (i) positive; ≥10 
B-cells with a kappa/lambda (K/L) ratio of >4 or <0.5, (ii) nega-
tive: B-cells with a K/L ratio between 0.5 and 4, and (iii) equivo-
cal; <10 B-cells with a K/L ratio of >4 or <0.5. For mature T- 
or NK-cell neoplasms, we selected surface markers according 
to the immunophenotypes of primary tumors characterized by 
immunohistochemistry or FCM. 7-AAD dye was used to select 
the viable cells [10]. A typical gating strategy is shown in Sup-
plemental Data Fig. 1. All monoclonal antibodies were from 
Becton Dickinson. 
3. Cytomorphology and CSF analysis
CSF samples were processed within several hours of collection 
and interpreted by a cytopathologist blinded to the FCM results. 
Liquid-based cytology (LBC) methods and Papanicolaou stain 
were used in the cytomorphological analysis as previously de-
scribed [11]. Results were reported as negative, positive, and 
equivocal for lymphoma on the basis of cellular morphology. 
Lymphocytes or abnormal cells with abnormal nuclear-cytoplas-
mic ratios and irregular nuclear morphologies were categorized 
as “equivocal”, which cannot be clearly categorized as “posi-
tive” [12]. WBC count was obtained by manual differential 
counting (100 WBCs), and protein and glucose levels were 
measured (COBAS Integra800, Roche Diagnostics, Mannheim, 
Germany).
4. Statistical analysis
The Mann-Whitney test was used to evaluate the difference of 
CSF protein, glucose, and WBC levels according to results of 
FCM or cytomorphology. A kappa value was calculated to inves-
tigate concordance rates. Kappa values over 0.8 were consid-
ered as good agreement. OS (Kaplan-Meier method) of DLBCL 
in FCM positive and FCM negative or equivocal cases was mea-
sured to analyze the prognostic effect of FCM-positive cases 
from the time of lymphoma diagnosis to death or last follow-up. 
A P value <0.05 was considered statistically significant. Statisti-
cal analysis was performed by using the PASW Statistics 20.0 
software (IBM, Armonk, NY, USA).
RESULTS
Fourteen (25.5%) of the 55 samples analyzed by FCM were 
positive, whereas only six (12.8%) of the 47 samples examined 
by cytomorphology were positive. All six cytomorphologically 
positive cases had positive results by FCM, while eight samples 
from seven patients were determined as positive by FCM but 
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negative or equivocal by cytomorphology (Table 1). FCM had 
lower rates of equivocal results than cytomorphology (2/55 vs. 
7/47), and the overall concordance between FCM and cytomor-
phology was 70.2% (kappa value=0.377, P <0.001). The low 
concordance rate was due to the low positive rates in cytomor-
phology (positive by FCM and negative by cytomorphology). The 
types of lymphoma in the positive cases are shown in Table 2.
The clinical characteristics of discrepant cases that were posi-
tive by FCM and negative/equivocal by cytomorphology are 
summarized in Table 3. Among these seven patients, four (pa-
tient no. 1, 5, 9, and 11) had history of LMD, and their CSF 
samples were obtained during treatment of LMD. Patients 1 and 
9 were initially positive by FCM and equivocal/negative by cyto-
morphology but were found to be positive by cytomorphology 
later in the follow-up study. The CD45-positive cells ranged from 
636 to 94,258 in these discrepant cases.
The clinical characteristics of other discrepant cases are sum-
marized in Table 4. Patients 3, 23, and 26 were negative by 
FCM and equivocal by cytomorphology, while patients 13 and 
20 were equivocal by FCM and negative by cytomorphology. All 
patients except patient 13 had histories of LMD (samples were 
obtained during treatment). The CD45-positive cells ranged 
from 437 to 12,349 in these discrepant cases. CSF protein and 
WBC levels were significantly higher in positive samples (deter-
mined by FCM) compared with negative samples, while CSF 
glucose levels were not significantly different (Table 5).
There was a trend that DLBCL cases positive by FCM have 
worse prognosis than DLBCL cases negative by FCM, but it did 
not reach statistical significance (P =0.139) probably owing to 
the small number of cases (Fig. 1).
DISCUSSION
The clinical significance of FCM for the detection of LMD has 
been evaluated in several studies thus far. In general, FCM has 
been found to be more sensitive compared with cytomorphology 
[6, 7, 13, 14]. For example, Di Noto et al. [14] reported positive 
rates of 26% and 9.5% by FCM and cytomorphology, respec-
tively, which are comparable to the present findings.
The clinical implication of patients who were positive by FCM 
and negative by cytomorphology has been evaluated in many 
studies [13-16]. Benevolo et al. [16] reported a higher risk of 
central nervous system (CNS) progression in such FCM-positive 
cases compared with those negative by both FCM and cytomor-
phology (hazard ratio=8.16). Likewise, Sancho et al. [17] re-
ported a higher CNS relapse or progression rate in such FCM-
positive cases compared with those negative by both methods 
(13% vs. 2.4%, P =0.04). Although our study did not show the 
adverse OS in cases which were positive by FCM, Hegde et al. 
[12] showed a high incidence of occult LMD (11 of 55 patients) 
using FCM in newly diagnosed non-aggressive B-cell lympho-
mas and an association with multiple metastasis of lymphoma. 
Bernstein et al. [18] suggested that methods can be used to 
Fig. 1. Overall survival in cases with diffuse large B cell lymphoma 
according to the results of flow cytometry (FCM).
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Table 1. Comparison of flow cytometry and cytomorphology in ce-
rebrospinal fluid from suspected cases of leptomeningeal diseases
FCM
Cytomorphology
Positive Negative Equivocal NA Total
Positive 6 5 3 - 14
Negative - 27 4 8 39
Equivocal - 2 - - 2
Total 6 34 7 8 55
Abbreviations: FCM, flow cytometry; NA, not available.
Table 2. Positive cases according to types of lymphoma
Positive
Flow cytometry Cytomorphology
Anaplastic large B-cell lymphoma 1 1
Burkitt lymphoma 
Diffuse large B cell lymphoma 9 4
Extranodal marginal zone lymphoma 1
Extranodal NK/T cell lymphoma 2 1
Mature T cell neoplasm, not otherwise
   specified  
1
14 (11 patients) 6 (5 patients)
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Table 3. Summary of discrepant cases that were positive by FCM and negative/equivocal by cytomorphology
Patient-
   sample
Age 
(yr)
Sex Histology
WBC count 
(×106/L)
FCM CM Reason for request IT-CTx
Positive in 
previous 
study
Positive in 
f/u study
Imaging study
1-1 45 F DLBCL 
   (neck LN)
40 P E f/u of LMD, brain, breast 
metastasis mental 
change
Yes Yes 
(by CM)
Yes 
(by CM)
1 month f/u PET: not 
evident LMD
1-2 2 P N 3 days after Yes Yes 
(by CM)
Yes 
(by CM)
3-3 46 M DLBCL 
   (brain)
1 P N Lower extremity weakness, 
dysuria 
Yes Yes 
(by CM)
No
5 53 M DLBCL 
   (neck LN)
18 P N f/u of recurred DLBCL 
(nasal cavity), diplopia
Yes No No Brain MRI: skull base 
enhancement
6* 51 M EMZL 
   (lung)
5 P E Brain imaging work-up –  
brain involvement
Yes No No Brain MRI: both cavernous 
sinus enhancement
7* 66 M Mature T cell 
   neoplasm 
   (small 
   intestine)
1 P N HLH, BM involvement No 
(expired)
No No Brain CT: not evident
9 48 M ENKTL 
   (nasal cavity)
5 P E f/u of recurred ENKTL  
(liver, BM) visual 
disturbance
Yes No Yes 
(by CM)
Orbit MRI: LMD
11 34 M DLBCL 
   (brain)
1 P N f/u of recurred (nasal 
cavity, brain) DLBCL, f/u 
of LMD
Yes Yes 
(by CM)
No Brain MRI: periventricular 
enhancement
*Initial work-up of primary hematologic malignancy.
Abbreviations; BM, bone marrow; CT, computed tomography; CM, cytomorphology; DLBCL, diffuse large B cell lymphoma; E, equivocal; EMZL, extranodal 
marginal zone lymphoma; ENKTL, extranodal NK/T cell lymphoma; FCM, flow cytometry; F, female; f/u, follow up; HLH, hemophagocytic lymphohistiocyto-
sis; IT-CTx, intrathecal chemotherapy; LMD, leptomeningeal disease; LN, lymph node; M, male; N, negative; NA, not available; P, positive; PET, positron 
emission tomography; MRI, magnetic resonance imaging.
Table 4. Summary of other cases showing discrepant results
Patient-
   sample
Age 
(yr)
Sex Histology
WBC 
count 
(×106/L)
FCM CM Reason for request IT-CTx
Positive in 
previous 
study
Positive in 
f/u study
Imaging study
3-2 46 M DLBCL (brain) 1 N E f/u of LMD Yes Yes
(by CM, FCM)
No MRI: persistent diffuse 
leptomeningeal abnormal 
enhancement
3-4 1 N E 10 days after Yes Yes
(by CM, FCM)
No
13 58 M Burkitt   
   lymphoma
   (terminal ilium)
1 E N Initial work up Yes No No No evidence (CT, MRI)
20 25 F DLBCL
   (stomach)
1 E N f/u of LMD seizure, altered 
mentality
Yes Yes 
(by CM)
No MRI: multifocal brain 
involvement
23 53 M DLBCL (brain) 4 N E f/u of multiple metastasis 
gait/visual disturbance
No Yes
(by CM)
No MRI: brain involvement
26 76 M DLBCL (brain) 48 N E f/u of recurred CNS DLBCL 
neck pain
No Yes
(by CM)
No MRI: diffuse leptomeningeal 
enhancement
Abbreviations; CNS, central nervous system; CT, computed tomography; CM, cytomorphology; DLBCL, diffuse large B cell lymphoma; E, equivocal; FCM, 
flow cytometry; F, female; f/u, follow up; IT-CTx, intrathecal chemotherapy; LMD, leptomeningeal disease; M, male; MRI, magnetic resonance imaging.
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detect subclinical CNS at diagnosis, such as using flow cytome-
try, and to develop better treatment strategies for patients with 
subclinical CNS. Thus, the use of FCM for high-risk patients at 
diagnosis and close follow-up or reevaluation is recommended 
in cases of occult LMD [13-16, 19].
Although the proportion is low, cases that are positive by cyto-
morphology and negative by FCM may also deserve special at-
tention from clinicians. Bromberg et al. [15] reported that these 
patients had higher frequency of clinical symptoms and pleocy-
tosis and poorer progression-free survival compared with pa-
tients who were positive by FCM only. Since false-negative re-
sults may occur during specimen processing (inadequate stor-
age temperature or prolonged storage) or owing to the presence 
of heterogeneous population (high proportion of normal lympho-
cyte with minor lymphoma cells) [20], the implementation of cy-
tomorphology in conjunction with FCM could be recommended 
[13, 15].
A major problem with the clinical use of FCM is the lack of 
standardized guidelines for sample preparation, antibody panel, 
interpretation criteria, and others. Moreover, sufficient amounts 
of CSF samples cannot be obtained easily, and the low volume 
and paucity of cells makes it difficult to interpret the results of 
FCM. Some efforts have been made to overcome these prob-
lems [19]. For example, multi-color FCM methods using three 
or more antibodies and the acquisition of sufficient number of 
CD45-positive cells in combination with viability selection have 
proven to increase sensitivity and reliability [7, 21-24]. Cesana 
et al. [7] reported that the diagnostic accuracy of FCM could be 
significantly improved by acquiring more than 220 CD45-posi-
tive cells. 
In conclusion, we have evaluated the use of FCM in CSF 
samples from patients clinically suspected of having LMD. We 
observed the higher prevalence of LMD by FCM than by cyto-
morphology. Although we did not observe an adverse prognostic 
effect of LMD determined by FCM, further studies would be 
needed to evaluate the diagnostic usefulness of FCM. 
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